Sanofi inaugurated the Charles Best Building, a new flu vaccine manufacturing facility in Toronto, Canada. The $925 million (CAD) investment aims to strengthen national pandemic preparedness.

The facility will manufacture Fluzone High-Dose, Sanofi’s influenza vaccine indicated for adults aged 65 years and older. This expansion adds end-to-end vaccine manufacturing capacity on Canadian soil.

Investment Structure

The project represents the single-largest investment in a biomanufacturing facility in Canadian history. It was built in partnership with multiple government entities:

• Government of Canada: $415 million
• Government of Ontario: $55 million

The remaining capital comes from Sanofi’s own investment. This public-private partnership model bolsters Canada’s vaccine biomanufacturing capabilities.

Strategic Context

Named after Dr. Charles Best, co-discoverer of insulin and early medical director at what is now the Sanofi Toronto Campus, the facility sits on Sanofi’s 52-acre property. The campus has deep roots in Canada’s biopharmaceutical history.

It has evolved into a major vaccine R&D and manufacturing hub. Vaccines produced here are distributed to more than 60 countries worldwide. The new building offers industrial-scale capacity to support Canada’s national response to future flu pandemics.

Official Inauguration

The Honourable Mélanie Joly, Canada’s Minister of Industry; The Honourable Marjorie Michel, Canada’s Minister of Health; The Honourable Doug Ford, Premier of Ontario; and Her Worship Olivia Chow, Mayor of Toronto joined Sanofi executives for the inauguration on Sept. 16, 2026.

Sanofi has entered into a strategic partnership with Cheplapharm, transferring 20 mature medicines and three manufacturing sites worldwide to the Swiss generic drugmaker in exchange for a 26.4% equity stake.

The deal, announced on September 14, 2026, builds on a collaboration that began in 2014. Sanofi will receive the equity stake as consideration for the asset transfer, marking a shift in its portfolio strategy to focus on innovation while retaining ownership interest in the acquiring entity.

Deal Structure

The transaction involves the handover of specific product lines and operational facilities. Key components include:

• Transfer of 20 mature medicine brands to Cheplapharm.
• Handover of three global manufacturing sites.
• Sanofi acquisition of a 26.4% equity stake in Cheplapharm.

Manufacturing Sites and Timeline

Three manufacturing sites will be transferred to Cheplapharm: Csanyikvölgy in Hungary (c.400 employees), Jurong in Singapore (c.100 employees), and Ploërmel in France (c.65 employees). Existing employment arrangements and collective agreements will be maintained.

The commercial transfer of the medicine portfolio is planned to begin in the first quarter of 2027. The site transfer will follow, subject to employee consultation procedures, regulatory approvals, and customary closing conditions. The transaction is expected to be fully completed by the third quarter of 2027.

Strategic Implications

The partnership reflects a shared conviction that innovative medicines and mature medicines require different operating models tailored to their specific manufacturing, regulatory, and commercial needs. Cheplapharm’s specialized expertise will ensure these medicines continue to meet patient needs throughout their lifecycle.

By converting asset value into an equity stake, Sanofi maintains exposure to the future performance of these mature products without bearing direct operational costs. The retention of a quarter-plus stake suggests confidence in the long-term cash flow potential of the transferred portfolio under Cheplapharm’s management.

Key Products and Financial Impact

The medicines being divested include Lovenox/Clexane (enoxaparin), excluding the US market. Cheplapharm Co-CEOs Edeltraud Lafer and Sebastian Braun noted that the project incorporates products complementing their extensive portfolio, including the expertise required to produce the flagship product Lovenox/Clexane.

Sanofi stated that the proposed transaction is not expected to have any impact on its financial guidance for 2026. Additional financial details are expected to be provided at a later stage.